Illinois Municipal Retirement Fund Purchases 9,586 Shares of Illumina, Inc. (NASDAQ:ILMN)

Illinois Municipal Retirement Fund raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 14.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,943 shares of the life sciences company's stock after acquiring an additional 9,586 shares during the period. Illinois Municipal Retirement Fund's holdings in Illumina were worth $6,105,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. IFP Advisors Inc lifted its stake in Illumina by 19.1% during the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock worth $82,000 after purchasing an additional 99 shares during the last quarter. Freedom Investment Management Inc. boosted its stake in shares of Illumina by 3.7% in the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock valued at $382,000 after purchasing an additional 101 shares in the last quarter. Personal CFO Solutions LLC grew its holdings in shares of Illumina by 9.2% during the 4th quarter. Personal CFO Solutions LLC now owns 1,789 shares of the life sciences company's stock valued at $239,000 after purchasing an additional 150 shares during the last quarter. GC Wealth Management RIA LLC raised its position in Illumina by 9.5% in the 4th quarter. GC Wealth Management RIA LLC now owns 1,783 shares of the life sciences company's stock worth $238,000 after purchasing an additional 154 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in Illumina by 16.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,108 shares of the life sciences company's stock valued at $148,000 after buying an additional 156 shares during the period. Institutional investors own 89.42% of the company's stock.

Illumina Stock Up 1.0%

Shares of ILMN traded up $0.97 during mid-day trading on Monday, reaching $95.76. The company had a trading volume of 265,868 shares, compared to its average volume of 2,135,340. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. The company has a market capitalization of $15.16 billion, a price-to-earnings ratio of -15.80, a price-to-earnings-growth ratio of 1.86 and a beta of 1.33. The firm has a 50-day moving average price of $82.69 and a 200 day moving average price of $98.65. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The company's quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.98 earnings per share. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Ankur Dhingra purchased 6,100 shares of the company's stock in a transaction dated Monday, May 12th. The shares were purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now directly owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.17% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ILMN shares. Guggenheim lowered their target price on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Barclays restated an "underweight" rating and issued a $85.00 target price (up previously from $77.00) on shares of Illumina in a report on Tuesday, June 24th. Stephens reaffirmed an "overweight" rating and issued a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Citigroup cut their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Finally, Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $127.39.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.